UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange
Act of 1934
Date of Report: April 12, 2017
Commission
File Number: 001-36891
|
Cellectis S.A. |
|
(Exact Name of registrant as specified in its charter) |
|
8, rue de la Croix Jarry |
|
75013 Paris, France |
|
+33 1 81 69 16 00 |
|
(Address of principal executive office) |
Indicate by
check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form
20-F ☑
Form 40-F ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): ⃞
Indicate by
check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ⃞
EXHIBIT INDEX
|
Exhibit |
Title |
|
|
99.1 |
Press release, dated April 12, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
CELLECTIS S.A. |
||
| (Registrant) | ||
|
April 12, 2017 |
By: |
/s/ André Choulika |
|
André Choulika |
||
|
|
Chief Executive Officer |
|
3
Exhibit 99.1
Cellectis S.A. to Explore Possible Initial Public Offering of Calyxt, Inc.
NEW YORK--(BUSINESS WIRE)--April 12, 2017--Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS) today announces that it is exploring the possibility of an initial public offering (IPO) of a minority interest in its plant sciences business, Calyxt, Inc. No decisions have been taken at this point on the structure or timing of any IPO, and no assurance can be given that an IPO will be pursued.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
CONTACT:
Media:
Jennifer Moore, 917-580-1088
VP of
Communications
media@cellectis.com
or
Caitlin Kasunich,
212-896-1241
KCSA Strategic Communications
ckasunich@kcsa.com
IR:
Simon
Harnest, 646-385-9008
VP of Corporate Strategy and Finance
simon.harnest@cellectis.com